Chronic myelogenous leukemia, BCR-ABL1 positive

Researchers are testing whether adding abatacept to standard immune-suppressing drugs can prevent severe graft-versus-host disease after a double umbilical cord blood transplant. The trial enrolls people with blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes…

This trial tests a new, lower-intensity combination of chemotherapy and radiation before a donor stem cell transplant for people with high-risk blood cancers or aplastic anemia. The goal is to see if this approach is safe enough to allow the donor cells to take hold and cure the …

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be life-threatening for people with weakened immune systems. The vaccine uses harmless virus pieces to train th…

This study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combin…

This study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…

This study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…

This study tests a combination of two drugs, dasatinib and venetoclax, in people with early chronic phase chronic myeloid leukemia (CML). The goal is to see if the combination can better control the disease by blocking enzymes that help cancer cells grow. About 155 participants w…

This early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…

This study tests whether reducing the dose of the cancer drug radotinib can still control chronic myeloid leukemia in its early phase while possibly easing side effects. Adults newly diagnosed with this blood cancer take a lower dose twice daily for up to a year. Researchers meas…

This phase III trial compares two oral drugs, radotinib and imatinib, in adults newly diagnosed with chronic myeloid leukemia in its chronic phase. Researchers want to see if radotinib, taken twice daily, achieves a deeper molecular response at 12 months than imatinib, taken once…

This study tests a new daily pill, asciminib, against several standard drugs for people newly diagnosed with a type of leukemia called CML. About 405 adults will be randomly assigned to receive either asciminib or a standard tyrosine kinase inhibitor (TKI). The main goal is to se…

This trial tests whether asciminib, a drug taken twice daily, can reduce leukemia burden in people with chronic phase chronic myeloid leukemia (CML) who have a specific T315I mutation. The study enrolls 50 adults in Germany, including those who had a stem cell transplant. The mai…

This study tests whether asciminib is easier to tolerate than nilotinib in adults newly diagnosed with a type of leukemia called Philadelphia chromosome-positive CML. About 568 participants take either asciminib once daily or nilotinib twice daily. The main goal is to see how lon…

This phase 2 trial compares two standard CML drugs—imatinib (Gleevec) at two different doses and dasatinib (Sprycel)—in 406 newly diagnosed patients with chronic phase CML. The main goal is to see which treatment leads to the best molecular response after 12 months, meaning a ver…

This early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…

This phase 2 trial is testing whether adding the experimental drug asciminib to standard treatments (imatinib, nilotinib, or dasatinib) can achieve deeper molecular responses in adults newly diagnosed with chronic-phase chronic myeloid leukemia (CML). Participants receive one of …

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…

This early-stage study tests a new drug called MGD024 in people with certain blood cancers (like leukemia and lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and watch for side effects. About 130 adults will receive…

This study tests a new drug, asciminib, as the first treatment for adults newly diagnosed with chronic myeloid leukemia (CML). If the drug alone does not achieve a deep response within 2 to 3 years, a low dose of another targeted therapy is added. The goal is to see if this appro…

This study looks at whether children with chronic myeloid leukemia (CML) who have very low levels of disease can stop taking their daily tyrosine kinase inhibitor (TKI) medication and still stay in remission. About 110 children will stop their TKIs and be closely monitored. If th…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This phase 2 trial tests whether adding lab-grown umbilical cord blood cells (dilanubicel) to a standard cord blood transplant helps people with blood cancers like leukemia recover their blood and immune cells faster. Participants receive chemotherapy and radiation to prepare the…

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This early-phase study tests a stem cell transplant method for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors give specially selected immune cells (regulatory T-cells) along with regular T-cells to help the body a…

This study looks at whether people with chronic myeloid leukemia (CML) who have had a stable, deep response to treatment for at least two years can safely stop taking their daily targeted therapy (TKI). It involves 17 adults who have been on TKI for over three years. The main goa…

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This study looks at whether people with chronic myeloid leukemia (CML) can stop taking their daily targeted therapy (TKI) without the cancer coming back. It compares two approaches: stopping the drug suddenly after a year of normal dosing, versus slowly reducing the dose over a y…

This program provides continued access to the drug vodobatinib for people with Philadelphia chromosome-positive chronic myeloid leukemia (CML) whose cancer has not responded to prior treatments. After the main study was stopped early for non-safety reasons, 29 patients who were s…

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This phase 2 trial tests whether adding ruxolitinib to a standard tyrosine kinase inhibitor (TKI) can help people with chronic myeloid leukemia (CML) stop their medication for longer. Participants had previously tried stopping a TKI but relapsed. The study enrolls 24 adults and m…

This early-stage trial tests a new oral drug called KQB198, alone or with another drug (dasatinib), in 13 adults with advanced blood cancers that have not responded to prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants tak…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This study tests a combination of two drugs, azacitidine and venetoclax, in people with a high-risk form of chronic myelomonocytic leukemia (CMML). The goal is to see if the combo can shrink or control the cancer better than current treatments. About 44 adults will take part, and…

This study looks at whether reducing the dose of the drug olverembatinib can still control chronic myeloid leukemia in patients who have already responded well to treatment. About 100 adults with chronic or accelerated phase CML will switch to a lower dose (20 mg every other day)…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…

This study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …

This phase 2 trial tests whether adding the drug tocilizumab to a standard transplant regimen can prevent graft failure and graft-versus-host disease in people with blood cancers receiving a special type of bone marrow transplant. The study involves 21 participants and aims to re…

This study tests whether giving palifermin and leuprolide acetate can help the immune system recover more quickly after a stem cell transplant for blood cancers like leukemia and lymphoma. About 82 participants will receive these drugs alongside their transplant. The goal is to s…

This study tests whether adding a drug called ruxolitinib to standard CML medications (like imatinib or dasatinib) can lower the amount of leukemia cells even more in people whose cancer is still detectable. About 81 adults with chronic phase CML will take part. The goal is to se…

This phase 2 trial tests whether starting with a stronger drug (ponatinib) for 6 months, then switching to a standard drug (imatinib) for at least 30 months, can help adults with newly diagnosed chronic myeloid leukemia reach deep remission. The goal is to see if patients can the…

This study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…

This study tests a stem cell transplant method that removes certain immune cells from the donor's blood to lower the chance of graft-versus-host disease (GvHD), a serious complication. It involves 3 patients with blood cancers or non-cancerous blood disorders who lack a perfectly…

This phase 2 trial tests asciminib, a daily oral drug, in 34 adults with chronic myeloid leukemia. Some participants have already tried one other treatment, while others are newly diagnosed. The study aims to see if asciminib can reduce cancer cells to very low levels. Doses may …

This study looks at whether taking nilotinib for two years can help people with chronic myeloid leukemia (CML) stay in remission after stopping their medication a second or third time. About 75 adults who previously tried and failed to stop treatment will take nilotinib and then …

This early-phase trial tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) after a mini stem cell transplant in people aged 60 and older with certain blood cancers. The study also aims to see if itacitinib allows doctors to use…

This study tests the drug bosutinib in 60 children with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Some children are newly diagnosed, while others have not responded to or cannot tolerate other treatments. The goal is to find the best dose and see if the…

This Phase 2 trial in Nigeria tests whether adding artesunate, a malaria drug, to the standard CML medication imatinib can improve treatment outcomes. 75 adults with chronic myeloid leukemia will receive either imatinib alone or imatinib plus artesunate. The goal is to see if the…

This early-phase study tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can prevent the virus from causing problems in blood cancer patients after a transplant. About 34 donor-recipient pairs are taking part. The vaccine is given to the donor before stem c…

Researchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…

This study looks at whether writing about their experiences can improve the health of Asian American breast cancer survivors. About 192 people who finished cancer treatment in the last 5 years will take part. They will write and report how they feel, and researchers will track an…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This was a planned French study to collect information on chronic myeloid leukemia (CML) in young adults aged 18 to 30 who were treated with tyrosine kinase inhibitors. The goal was to describe their diagnosis, treatment choices, side effects, and quality of life. However, the st…

This study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather pra…

This study follows 144 blood cancer patients undergoing stem cell transplants to see how muscle function changes and whether it predicts complications like infections, relapse, or survival. Researchers will measure muscle mass and track medical events over time. The goal is to un…